Microfluidics (lab-on-a-chip) is a promising technology for an extremely broad range of biomedical applications including drug discovery; tissue engineering; point-of-care diagnostics; and cancer screening based on rare cell detection, protein, DNA, or micro-RNA biomarkers, and circulating exosomes. This proposal aims to revolutionize the biomedical microfluidic ecosystem by developing 3D printing to routinely create very small, densely integrated microfluidic devices for the biomedical sciences. Such devices are not possible with conventional microfluidic fabrication techniques, which typically rely on careful alignment and bonding of a handful of individually fabricated layers, each of which has a 2D component layout. In contrast, 3D printing permits all 3 dimensions of the device volume to be fully utilized for component placement and channel routing, offering the opportunity for dense component integration and small device volume. Moreover, short print times enable fast fabrication and test cycles to dramatically speed device development. This proposal intends to initiate a virtuous cycle in which 3D printed microfluidics becomes a disruptive tool for biomedical innovation, which should have a substantial impact on human health. To date, the key inhibiting factor for 3D printing has been the inability of commercial 3D printers and resins to fabricate the requisite microvoids that comprise microfluidic structures. Our results from the previous grant period demonstrate that with the custom 3D printer and resin formulations we have designed and optimized, we can 3D print microfluidic devices with channels as small as 18 m x 20 m, valves only 150 m in diameter, highly integrated pumps and mixers, and high density (88/mm2) chip-to-chip interconnections containing integrated microgaskets. Moreover, we have developed a new, inexpensive, open-source, biocompatible resin suitable for cell-based work.
Aim 1 of this proposal will focus on developing new tools for higher resolution 3D printing of microfluidic devices to generate novel, previously unobtainable structures and properties.
Aim 2 will develop devices with high resolution porous membranes and functionalizble resin formulations.
Aim 3 will develop and validate device performance using a direct cell-based chemotactic migration assay. In short, in this proposal we will leverage and extend our 3D printer and resin technologies to innovatively reduce fluidic feature sizes to ~3 m and create functionalizable, porous membranes for cell-based adhesion and migration assays in devices with 3D geometries that are printed in 15 minutes.
The proposed research will develop the advanced 3D printing technology needed to make very small yet highly sophisticated lab-on-a-chip (microfluidic) devices to accelerate biomedical innovation. Such devices are used in many medical applications including drug discovery, tissue engineering, cancer screening, point-of-care diagnostics, and pathogen detection. Our focus will be on development of tools, methods, and devices for cell-based biomedical research and innovation.
| Gong, Hua; Woolley, Adam T; Nordin, Gregory P (2018) 3D printed high density, reversible, chip-to-chip microfluidic interconnects. Lab Chip 18:639-647 |
| Parker, Ellen K; Nielsen, Anna V; Beauchamp, Michael J et al. (2018) 3D printed microfluidic devices with immunoaffinity monoliths for extraction of preterm birth biomarkers. Anal Bioanal Chem : |
| Beauchamp, Michael J; Gong, Hua; Woolley, Adam T et al. (2018) 3D Printed Microfluidic Features Using Dose Control in X, Y, and Z Dimensions. Micromachines (Basel) 9: |
